All In Biotech

Drug Trial Radar · NCT04250363

Chemoprophylactic Activity of M5717 in PfSPZ Challenge Model

A Phase Ib, Randomized, Double-Blind, Placebo Controlled, Sequential Study of Single Oral Doses of M5717 to Explore the Chemoprophylactic Activity of M5717 in a Controlled PISPZ Challenge Model in Healthy Participants

Last checked: Nov 19, 2026Latest source record: May 1, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

39

Actual

Start

Feb 17, 2020

Primary completion

Aug 18, 2021

Study completion Aug 18, 2021

Sponsor

Sponsor type
Industry
First posted
Jan 31, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Double (participant, investigator)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The main purpose of this study was to assess the chemoprophylactic activity and dose-exposure-response relationship of single oral dose of M5717 administered after direct intravenous inoculation (DVI) of Plasmodium falciparum sporozoite (PfSPZ) challenge in healthy participants.

Conditions

  • Healthy

Interventions

  • PfSPZ ChallengeBiological

    Participants received 3200 units of Plasmodium falciparum sporozoites by DVI on Day 1.

  • PalceboDrug

    Participants received single oral dose of placebo matched to M5717 capsule on Day 1.

  • M5717 30 mgDrug

    Participants received 30 mg single oral dose of M5717 capsule on Day 1.

  • M5717 60 mgDrug

    Participants received 60 mg single oral dose of M5717 capsule on Day 1.

  • M5717 80 mgDrug

    Participants received 80 mg single oral dose of M5717 capsule on Day 1.

  • M5717 100 mgDrug

    Participants received 100 mg single oral dose of M5717 capsule on Day 1.

  • M5717 200 mgDrug

    Participants received 200 mg single oral dose of M5717 capsule on Day 1.

  • PlaceboDrug

    Participants received single oral dose of placebo matched to M5717 capsule on Day 5.

  • M5717 60 mgDrug

    Participants received 60 mg single oral dose of M5717 capsule on Day 5.

  • M5717 100 mgDrug

    Participants received 100 mg single oral dose of M5717 capsule on Day 5.

  • M5717 200 mgDrug

    Participants received 200 mg single oral dose of M5717 capsule on Day 5.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Early Liver Stage: Number of Participants Over Time With Positive ParasitemiaTime frame: Early Liver Stage: From Day 1 up to Day 28
  2. Late Liver Stage: Number of Participants Over Time With Positive ParasitemiaTime frame: Late Liver Stage: From Day 5 up to Day 32
  3. Early Liver Stage: Time to First Positive Parasitemia Based on Quantitative Polymerase Chain Reaction (qPCR)Time frame: Early Liver Stage: From Day 1 up to Day 28
  4. Late Liver Stage: Time to First Positive Parasitemia Based on Quantitative Polymerase Chain Reaction (qPCR)Time frame: Late Liver Stage: From Day 5 up to Day 32
  5. Early Liver Stage: Number of Participants With Documented Blood Stage Parasite GrowthTime frame: Early Liver Stage: From Day 1 up to Day 28
  6. Late Liver Stage: Number of Participants With Documented Blood Stage Parasite GrowthTime frame: Late Liver Stage: From Day 5 up to Day 32
  7. Early Liver Stage: Clinical Symptoms of Malaria Assessed Using Malaria Clinical ScoreTime frame: Early Liver Stage: At Day 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 22, 24, 26 and 28
  8. Late Liver Stage: Clinical Symptoms of Malaria Assessed Using Malaria Clinical ScoreTime frame: Late Liver Stage: At Day 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 26, 28, 30 and 32
  9. Dose Exposure Response Relationship of M5717 Assessed by Logistic Regression ModelTime frame: From Day 5 up to Day 32

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Leiden University Medical Center

    Leiden, Netherlands

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.